The Prognostic Significance of Thrombocytosis in Epithelial Ovarian Carcinoma
Overview
Affiliations
Objective: The objective of this study was to determine the incidence of thrombocytosis in epithelial ovarian carcinoma and examine associations with clinico-pathologic features. Thrombocytosis (platelet counts >400 x 10(9)/l) has been identified as a poor prognostic factor in many cancers. Platelet-secreted factors may contribute to metastasis, invasion, and primary tumor growth.
Methods: One hundred eighty-three patients with invasive epithelial ovarian or primary peritoneal carcinomas were identified between January 1996 and December 2000. Records were retrospectively reviewed and data analyzed using chi(2), Student's t test, and Cox proportional hazards model; survival was analyzed by the method of Kaplan and Meier.
Results: Forty-one of 183 (22.4%) patients had thrombocytosis at primary diagnosis. Patients with preoperative thrombocytosis were found to have greater elevations of CA-125 (P = 0.026), more advanced stage disease (P = 0.016), higher grade tumors (P = 0.010), more frequent lymph node metastases (P = 0.018), and greater volume of ascites (P < 0.0001). One hundred sixty of 183 (87.4%) patients achieved optimal cytoreduction; patients with thrombocytosis demonstrated a greater likelihood of suboptimal resection (residual disease >1 cm; 19/41 vs. 4/142 in patients without thrombocytosis, P < 0.0001). Patients with thrombocytosis had a shorter disease-free interval (12 vs. 34 months, P < 0.0001) and overall survival (28 vs. 79 months, P < 0.0001). On multivariate analysis, thrombocytosis retained significance as a poor prognostic indicator in patients with stage III and IVA disease (P = 0.04).
Conclusions: Thrombocytosis is a frequent preoperative finding in ovarian and peritoneal carcinomas and may be a marker of aggressive tumor biology.
Said S, IntHout J, den Ouden J, Walraven J, van der Aa M, de Hullu J J Clin Med. 2024; 13(10).
PMID: 38792332 PMC: 11122536. DOI: 10.3390/jcm13102789.
Pre-treatment thrombocytosis and ovarian cancer survival: A meta-analysis.
Pergialiotis V, Vogiatzi Vokotopoulou L, Vlachos D, Liontos M, Kontomanolis E, Thomakos N Eur J Obstet Gynecol Reprod Biol X. 2024; 22:100312.
PMID: 38745890 PMC: 11091518. DOI: 10.1016/j.eurox.2024.100312.
Role of reactive thrombocytosis after primary cytoreductive surgery in advanced ovarian cancer.
Kim M, Baek S, Noh J, Shim J, Kang J, Jeong S Front Oncol. 2022; 12:926878.
PMID: 36158646 PMC: 9493080. DOI: 10.3389/fonc.2022.926878.
Xia S, Wu W, Yu L, Ma L, Chen S, Wang H Medicine (Baltimore). 2022; 101(35):e30275.
PMID: 36107503 PMC: 9439792. DOI: 10.1097/MD.0000000000030275.
Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review.
Liberto J, Chen S, Shih I, Wang T, Wang T, Pisanic 2nd T Cancers (Basel). 2022; 14(12).
PMID: 35740550 PMC: 9221480. DOI: 10.3390/cancers14122885.